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Abstract
Introduction Liver dysfunction associated with artificial nutrition
in critically ill patients is a complication that seems to be
frequent, but it has not been assessed previously in a large
cohort of critically ill patients.
Methods We conducted a prospective cohort study of
incidence in 40 intensive care units. Different liver dysfunction
patterns were defined: (a) cholestasis: alkaline phosphatase of
more than 280 IU/l, gamma-glutamyl-transferase of more than
50 IU/l, or bilirubin of more than 1.2 mg/dl; (b) liver necrosis:
aspartate aminotransferase of more than 40 IU/l or alanine
aminotransferase of more than 42 IU/l, plus bilirubin of more
than 1.2 mg/dl or international normalized ratio of more than 1.4;
and (c) mixed pattern: alkaline phosphatase of more than 280
IU/l or gamma-glutamyl-transferase of more than 50 IU/l, plus
aspartate aminotransferase of more than 40 IU/l or alanine
aminotransferase of more than 42 IU/l.
Results Seven hundred and twenty-five of 3,409 patients
received artificial nutrition: 303 received total parenteral
nutrition (TPN) and 422 received enteral nutrition (EN). Twenty-
three percent of patients developed liver dysfunction: 30% in
the TPN group and 18% in the EN group. The univariate analysis
showed an association between liver dysfunction and TPN (p <
0.001), Multiple Organ Dysfunction Score on admission (p <
0.001), sepsis (p < 0.001), early use of artificial nutrition (p <
0.03), and malnutrition (p < 0.01). In the multivariate analysis,
liver dysfunction was associated with TPN (p < 0.001), sepsis
(p  < 0.02), early use of artificial nutrition (p  < 0.03), and
calculated energy requirements of more than 25 kcal/kg per day
(p < 0.05).
Conclusion TPN, sepsis, and excessive calculated energy
requirements appear as risk factors for developing liver
dysfunction. Septic critically ill patients should not be fed with
excessive caloric amounts, particularly when TPN is employed.
Administering artificial nutrition in the first 24 hours after
admission seems to have a protective effect.
APACHE II = Acute Physiology and Chronic Health Evaluation II; CI = confidence interval; EN = enteral nutrition; ICU = intensive care unit; INR = 
international normalized ratio; IQ = interquartile; LCT = long-chain triglyceride; LD = liver dysfunction; MCT = medium-chain triglyceride; MODS = 
Multiple Organ Dysfunction Score; OR = odds ratio; TPN = total parenteral nutrition.Critical Care    Vol 11 No 1    Grau et al.
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Introduction
Artificial nutrition support is part of the standard of care in crit-
ically ill patients [1]. Some of these patients have sepsis or
systemic inflammatory response syndrome, which produce
hypermetabolism, accelerated lipolysis, insulin resistance, and
protein catabolism. These phenomena, associated with the
lack of oral intake, can lead to malnutrition. Artificial nutrition
usually does not reverse these metabolic derangements but
can decrease the depletion of the lean body mass [2]. Hepa-
tobiliary complications related to artificial nutrition have been
widely reported, particularly in patients receiving total
parenteral nutrition (TPN), and less frequently in patients
receiving enteral nutrition (EN) [3]. There are many potential
causes of liver dysfunction (LD) related to artificial nutrition,
but the etiology is unclear and there are few data on the prev-
alence in critically ill patients. Moreover, these patients can
present hepatic dysfunction as part of the multiple organ fail-
ure syndrome [4]. The aim of this study was to assess the prev-
alence of hepatobiliary complications related to artificial
nutrition, the risk factors associated with these complications,
and their influence on the prognosis in critically ill patients.
Materials and methods
Design
This study was designed as a multicenter prospective cohort
study of incidence of LD in patients admitted to any of the 40
participating intensive care units (ICUs) from tertiary hospitals
in Spain between 1 March and 15 April 2000. Patients were
enrolled consecutively when the treating physician expected
them to need artificial nutrition for five days or more. The pro-
tocol and definitions of LD were established previously in a
meeting with the participants. The institutional review board of
each participating hospital approved the study. Informed con-
sent was waived according to these boards and Spanish law.
Our funding sources had no role in the acquisition, analysis, or
interpretation of data or in the submission of this report.
Patients
Patients entered in the study were followed prospectively until
hospital discharge or 28 days after ICU admission to check
mortality at that time. Age, gender, weight, primary diagnosis,
group (medical, surgical, or trauma), APACHE II (Acute Phys-
iology and Chronic Health Evaluation II) score [5], Multiple
Organ Dysfunction Score (MODS) [4], the need for mechani-
cal ventilation, and the presence and origin of sepsis and/or
septic shock were recorded on admission. The diagnosis of
sepsis or septic shock on admission was made according to
previously published criteria [6]. Sepsis was defined when a
patient had a confirmed infection with two or more of the fol-
lowing criteria: (a) temperature greater than 38°C or less than
36°C, (b) heart rate greater than 90 beats per minute, (c) res-
piratory rate greater than 20 respirations per minute or PaCO2
(partial pressure of carbon dioxide) less than 32 mm Hg, and
(d) leukocytes greater than 12,000 per cubic millimeter or
greater than 10% band neutrophils. Septic shock was defined
as arterial hypotension induced by sepsis, which persists in
spite of the adequate replacement of fluids and associated
with hypoperfusion and organ dysfunction. Exclusion criteria
were age of less than 18 years, expected survival of less than
24 hours, or previous cardiopulmonary resuscitation. Patients
with previously recognized liver disease were excluded by the
following criteria: (a) portal hypertension with gastrointestinal
bleeding at the time of admission and/or transfer, (b) clinically
apparent ascites on a hepatocellular basis, (c) total bilirubin of
more than 3 mg/dl or aspartate aminotransferase of more than
40 IU/l or on a hepatocellular basis, (d) serum albumin of less
than 0.03 g/l with portal hypertension, (e) encephalopathy of
grade II or greater, and (f) clinical diagnosis of alcoholic hepa-
titis [7].
Choice of the type of nutrition
The clinician responsible for the patient chose the type of nutri-
tion, the administration route, and the type of diet following the
published recommendations [8]. The protocol was discussed
in previous meetings with the researchers. The use of early
artificial nutrition was encouraged to the participants. EN was
recommended as the preferred route for feedings if the
patient's gastrointestinal system was preserved. Clinicians
could switch to TPN if the patient did not tolerate EN due to
gastrointestinal complications or if 75% of the caloric require-
ments were not achieved after three days of enteral feedings.
Also, clinicians were allowed to administer EN for as long as
the gastrointestinal function was recovered. In both cases, the
amount of calories was limited to the planned caloric intake.
TPN was administered through a central venous catheter, with
the use of 'all in one' ternary mixtures, by means of a continu-
ous pump infusion. The TPN bag was replaced every 24 hours.
EN was administered through a nasogastric or nasojejunal
tube at the doctor's discretion and continuously through an
infusion pump in accordance with a previously established
protocol [9]. The systems used for EN administration were
replaced at least once a day, and the feeding tube was flushed
on a shift basis three times a day with 20 ml of distilled water.
Malnutrition was assessed by means of the Subjective Global
Assessment [10]. The calculated nutritional requirements
were 25 kcal/kg per day (using the actual weight) with an
intake of 1 to 1.5 g of protein/kg per day and a ratio of carbo-
hydrates/fat of 60:40, in agreement with the recommenda-
tions published by the SEMICYUC (Spanish Society of
Intensive Care) [11]. Fats used in the TPN group were long-
chain triglyceride (LCT) or a physical admixture of medium-
chain triglyceride (MCT)/LCT, according to the practice of
each center. Enteral diets used in the EN group were always
polymeric. Once the nutrition had been started, the following
parameters were recorded: blood sugar and glucosuria every
six hours; urea, creatinine, sodium, potassium, and chlorine
every 24 hours; and a weekly analysis that included choles-
terol, triglycerides, phosphorus, calcium, magnesium, and
osmolarity. Liver function tests (total and direct bilirubin, aspar-
tate aminotransferase, alanine aminotransferase, gamma-Available online http://ccforum.com/content/11/1/R10
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glutamyl-transferase, and alkaline phosphatase), prothrombin
time, and international normalized ratio (INR) were recorded
on admission and twice a week (on Tuesday and Friday). The
withdrawal of artificial nutrition was defined as the definitive
suppression of artificial nutrition, and suspension was defined
as a temporary cancellation not longer than 24 hours.
Definitions
The criteria used in this study to define the patterns of LD were
the following: (a) cholestasis: alkaline phosphatase of more
than 280 IU/l, gamma-glutamyl-transferase of more than 50 IU/
l, or bilirubin of more than 1.2 mg/dl; (b) liver necrosis: aspar-
tate aminotransferase of more than 40 IU/l, alanine ami-
notransferase of more than 42 IU/l, or INR of more than 1.4;
and (c) mixed pattern: alkaline phosphatase of more than 280
IU/l, gamma-glutamyl-transferase of more than 50 IU/l, or
bilirubin of more than 1.2 mg/dl, plus aspartate aminotrans-
ferase of more than 40 IU/l, alanine aminotransferase of more
than 42 IU/l, or INR of more than 1.4. These boundaries repre-
sent a 10% increase of the normal values in the reference lab-
oratories used. LD was diagnosed when any of the previously
defined enzymatic alterations were present. The diagnosis of
acalculous cholecystitis was based on clinical criteria and
ultrasound. Liver biopsies were not carried out in this study.
Statistical analysis
An intention-to-treat analysis was done for both types of nutri-
tion, TPN and EN. The newly created database was central-
ized and managed by the main researchers. Any doubts about
application of the protocol were discussed with the partici-
pants, and the main researchers made the final decision. Once
the time of the study was over, the database was closed down.
The analysis was blind to the type of nutrition used. The statis-
tical analysis was performed using the SPSS v12 program
(SPSS Inc, Chicago, Illinois, USA). The quantitative values
were analyzed for normality. The values with normal distribu-
tion were compared using the Student's t test, and the others
using non-parametric tests (Kruskall-Wallis test). The qualita-
tive values were compared using Fisher's uncorrected chi-
square test, and we calculated the relative risk with the confi-
dence interval (CI) set at 95%. Statistical significance was set
at p less than 0.05. The quantitative data were expressed as a
median and interquartile (IQ) range, and the qualitative data
were expressed in absolute values and percentages. The mul-
tivariate analysis for LD was carried out by means of a 'step-
wise forward' logistical regression model with the most
important demographic variables and those that reached sta-
tistical significance in the univariate analysis. Time free of LD
was analyzed using the Kaplan-Meyer test.
Results
Description of the population
Three thousand four hundred and nine patients were admitted
during the study. Seven hundred and fifty-six patients received
nutrition in some form, whether TPN or EN, but 31 were
excluded and 725 were studied (Table 1). Four hundred and
eighty-eight were men and 237 were women. Three hundred
and three patients (41.8%) received TPN and 422 (58.2%)
received EN as the initial treatment. The patients who received
TPN were older than those treated with EN (66 years, IQ
range 48 to 73 years, versus 61 years, IQ range 45 to 71
years; p < 0.01) and mainly were women (38% versus 29%;
p < 0.05). TPN was mostly used in surgical patients (175/264
versus 89/264; p < 0.001). Two hundred and eight patients
had sepsis on admission; of these patients, 105 had septic
shock. In both cases, TPN was used more frequently than EN.
APACHE II score was higher in the group of patients who
received EN (19, IQ range 13 to 23, versus 17, IQ range 12
to 22), without reaching statistical significance. More patients
in the EN group required mechanical ventilation (91% versus
79%;  p  < 0.001). Also, ICU length of stay was longer in
patients who received EN (12 days, IQ range 7 to 21 days,
versus 8 days, IQ range 5 to 17 days; p < 0.001). Mortality,
assessed 28 days after admission, showed no significant dif-
ferences in either group (Table 2).
The nutritional parameters were different in the two groups of
patients. There was a significant statistical association
between TPN and severe malnutrition (36% versus 15%; p <
0.001). The calculated energy requirements were similar in
both groups as well as the days of artificial nutrition. Nutrition
was started early after admission in both groups (median: 1
day, IQ range: 0 to 2 days), without differences between them.
The duration of artificial nutrition was also similar in both
groups (median: 9 days, IQ range: 5 to 8 days). One hundred
and twenty-two patients assigned to the TPN group received
EN when the gastrointestinal function recovered, and EN was
stopped in 67 because they were unable to achieve the caloric
requirements at day 3 or because they had EN-related compli-
cations. MCT/LCT admixtures were used in both groups when
receiving TPN, without differences between them. Patients
with EN received significantly fewer calories per kilogram on
day 1 (20.8, IQ range 15.7 to 25, versus 22.9, IQ range
217.57 to 27.67; p < 0.01) and day 3 of the study (22.5, IQ
range 17.65 to 26.87, versus 24.1, IQ range 20 to 29.45; p <
0.005) (Table 3).
LD and artificial nutrition
One hundred and sixty-six patients (23%) had LD. There was
a significant statistical association between the appearance of
LD and age (p < 0.01), the MODS score (p < 0.001), in sur-
gical (35%) and trauma patients (41%) (p < 0.03), if they had
sepsis (p < 0.001) or septic shock on admission (p < 0.02),
and in patients who were mechanically ventilated (p < 0.02).
The stay in the ICU (16 days, IQ range 8 to 28 days, versus 9
days, IQ range 5 to 17 days; p < 0.001) and in the hospital (28
days, IQ range 17 to 29 days, versus 23 days, IQ range 14 to
28 days; p < 0.01) was longer in the group with LD. No differ-
ence in mortality was shown between the two groups (Table
4). The patients with LD were less nourished (33% versusCritical Care    Vol 11 No 1    Grau et al.
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21%; p < 0.01) and were treated mostly with TPN (30% ver-
sus 18%; p < 0.001) for more days (13 days, IQ range 8 to
25, versus 8 days, IQ range 4 to 16 days; p < 0.001). Patients
fed early had significantly less LD. The use of MCT/LCT admix-
tures was similar in patients with or without LD, but the calcu-
lated energy requirements were higher (25.54 kcal/kg per day,
IQ range 24.49 to 30 kcal/kg per day, versus 25 kcal/kg per
day, IQ range 23.33 to 29.41 kcal/kg per day; p < 0.05) (Table
5).
LD, TPN, and type of patients
In the univariate analysis, 91 patients treated with TPN devel-
oped some form of LD but only 75 in the EN group did (odds
ratio [OR] 1.7, 95% CI 1.3 to 2.2) (Table 6). Surgical patients
(31% versus 16%; OR 1.8, 95% CI 1.02 to 3.1) and trauma
patients (52% versus 23%; OR 2.1, 95% CI 1.1 to 4) treated
with TPN had more LD. This association was maintained for all
types of LD: cholestasis (OR 1.7, 95% CI 1.04 to 2.9), liver
necrosis (OR 1.95, 95% CI 1.1 to 3.42), and mixed pattern
(OR 1.8, 95% CI 1.3 to 2.6). The patients with sepsis and TPN
showed a higher incidence of LD than the group treated with
EN (39% versus 24%; OR 1.6, 95% CI 1.02 to 2.4), although
no type of LD was greater in either group. When looking at the
time free of LD, EN increased the time free of disease in surgi-
cal patients only in the Kaplan-Meyer survival test (Figure 1).
Only three patients were diagnosed with acalculous
cholecystitis.
Multivariate analysis
The risk factors associated with LD in the multivariate analysis
were TPN (OR 1.96, 95% CI 1.3 to 2.97, p < 0.001), the early
use of artificial nutrition (TPN or EN) the first day after admis-
sion (OR 0.6, 95% CI 0.4 to 0.9, p < 0.01), MODS (OR 1.1,
95% CI 1.04 to 1.2, p < 0.001), and the diagnosis of sepsis
on admission (OR 1.76, 95% CI 1.08 to 2.9, p < 0.02). The
rest of the variables analyzed, such as age, gender, APACHE
II score, septic shock on admission, medical patients, surgical
patients, mechanical ventilation, the use of MCT/LCT
admixtures, or severe malnutrition, did not reach statistical sig-
nificance in the logistical regression model (Table 7).
Discussion
Our study shows that the incidence of LD associated with arti-
ficial nutrition in seriously ill patients is low (23%) and is more
frequent in patients who received TPN, with sepsis on admis-
sion, and when the planned calculated caloric intake was
higher than 25 kcal/kg per day. LD is a widely recognized
complication associated with the use of artificial nutrition, par-
ticularly TPN, with an incidence of between 25% and 100%
[12,13]. Acalculous cholecystitis was diagnosed in only three
patients who received TPN, with an incidence of close to the
4% published elsewhere [12].
Multiple factors are related to LD associated with TPN, linked
to the type of formulation or the appearance of nutritional defi-
ciencies with the use of TPN [13-16]. Some of these factors
are shortage of essential fatty acids [17,18], excessive caloric
intake [19], imbalance in the composition of the amino acids
[20] or of the non-protein substrates [21], fat deposit in the
liver [22], a caloric intake based exclusively on fats [23], a
cholestatic effect of the amino acids [24], the absence of
choline [25], production of endotoxins and lithocholic acid due
to intestinal bacterial overgrowth [26], shortage of carnitine
[27], or the absence of enteral nutritional intake [28,29].
However, few studies examine the risk factors attributable to
the clinical state of the patient. The aims of this study were to
identify the relationship between the appearance of LD and
the use of artificial nutrition and to identify the contributing
factors specific to the critically ill patient (severity scores,
associated co-morbidity such as sepsis, and mechanical ven-
tilation) which can act as confusion factors. Many studies have
demonstrated the superiority of EN over TPN, both in surgical
patients [30-33] and in patients admitted to the ICU [34,35].
Our results show that patients who received EN had a lower
incidence of LD. Most patients who received EN were medi-
Table 1
Patient flow through the study
Patients admitted to the intensive care unit 3,409
Patients without artificial nutrition 2,653
Patients with artificial nutrition 756
Patients excluded 31
Patients studied 725
Patients on total parenteral nutrition 303
Patients also receiving enteral nutrition* 122
Patients on enteral nutrition 422
Patients also receiving total parenteral nutrition** 67
* Group of patients who received enteral nutrition after TPN
** Group of patients who received TPN after enteral nutritionAvailable online http://ccforum.com/content/11/1/R10
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Table 2
Demographic data
TPN EN Total p
Number of patients 303 422 725
Women 114 (38%) 123 (29%) 237 (33%) 0.02
Age in years 66 (48–73) 61 (45–71) 63 (47–72) 0.01
APACHE II score 17 (12–22) 19 (13–23) 18 (12–22) 0.08
MODS 5 (3–8) 5 (3–7) 5 (3–7) 0.95
Primary diagnosis 0.001
Gastrointestinal surgery 145 33 178
Respiratory failure 21 112 133
Stroke 22 103 125
Cardiovascular 36 50 86
Trauma 19 64 83
Infections in non-immunosuppressed patients 18 22 40
Infections in immunosuppressed patients 4 7 11
Metabolic diseases 5 5 10
Urology 4 6 10
Hematology 7 2 9
Poisoning 4 4 8
Obstetrics/Gynecology 6 1 7
AIDS 1 1 2
Other 11 12 23
Type of patients 0.001
Medical 105 257 362
Surgical 175 89 264
Trauma 23 76 99
Sepsis on admission 122 (40%) 86 (20%) 208 (29%) 0.001
Septic shock on admission 70 (23%) 35 (8%) 105 (15%) 0.001
Patients on mechanical ventilation 239 (79%) 382 (91%) 621 (86%) 0.001
Days of mechanical ventilation 7 (2–16) 9 (4–17) 8 (3–16) 0.001
Intensive care unit length of stay in days 8 (5–17) 12 (7–21) 10 (6–20) 0.001
Hospital length of stay in days 25 (15–29) 25 (15–28) 25 (15–29) 0.6
Mortality at 28 days 85 (28.1%) 119 (28.2%) 204 (28%) 0.9
Parenthetical values indicate range or percentage. APACHE II, Acute Physiology and Chronic Health Evaluation II; EN, enteral nutrition; MODS, 
Multiple Organ Dysfunction Score; TPN, total parenteral nutrition.Critical Care    Vol 11 No 1    Grau et al.
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cal, were more in need of mechanical ventilation, and had a
longer stay in the ICU but showed less LD (18% in the EN
group versus 30% in the TPN group). This result is strong
enough because we have performed an 'intention to treat anal-
ysis,' and the 16% of the patients on EN also received TPN.
We have found that other factors, such as previous gastroin-
testinal surgery or sepsis on admission, can explain the greater
incidence of LD shown in the results of our study and in other
studies [36,37].
Our study shows that cholestasis and the mixed pattern are
the two most frequent types of LD. The elevations of serum
transaminases, alkaline phosphatase, and bilirubin are the
changes most often associated with the use of TPN [38,39].
Although the increase of serum transaminases usually takes
place in the first two or three weeks of TPN, it is unusual to
observe a significant increase of bilirubin in this period, at least
in adult patients [40-42]. In many cases, these enzymatic alter-
ations are mild and transient, even without the interruption of
TPN, and only occasionally lead to liver steatosis. Fat infiltra-
tion and intrahepatic cholestasis are the typical findings in
these patients [28,43,44]. The progress of this LD is generally
self-limiting but can lead to liver failure in a minority of patients
[38,39,44]. Liver biopsies showed that the predominant find-
ing in patients with enzymatic alterations is liver steatosis
[3,11]. When biopsies are carried out in different periods of
time, steatosis is an early and sometimes transient phenome-
non, whereas cholestasis is a later finding and generally per-
sists during the TPN. Nevertheless, there are contradictory
data between an abnormal level of the hepatic enzymes and
steatosis or cholestasis [43,44]. Interestingly, our data show
that the early use of artificial nutrition, TPN or EN, can delay the
Table 3
Nutritional parameters
TPN EN Total p
303 422 725
Weight 70 (63–80) 73 (65–80) 72 (65–80) 0.2
Nutritional status 0.001
Moderate malnutrition 76 (25%) 49 (12%) 125 (17%)
Severe malnutrition 33 (11%) 14 (3%) 47 (7%)
Energy requirements per kilogram 25 (23.29–29.37) 25 (23.76–30) 25 (23.64–29.74) 0.7
Patients receiving TPN - 67
Patients receiving EN 122 -
Patients receiving MCT/LCT on TPN 186 (61%) 47 (71%) 233 (63%) 0.2
Days of artificial nutrition 8 (4–18) 10 (5–19) 9 (5–8) 0.2
Days on EN 1 (0–1) 9 (5–18) 6 (1–13) 0.001
Days on TPN 7 (3–11) 0 (0–1) 1 (0–7) 0.001
Starting time after ICU admission in days 1 (0–2) 1 (0–2) 1 0–2) 0.6
Prescribed caloric intake per kilogram on day 1 24.65 (18.77–28.57) 23.53 (20.00–26.67) 24 (19.3–27.64) 0.09
Administered caloric intake per kilogram on day 1 22.92 (17.57–27.67) 20.8 (15.72–25) 21.43 (16.36–26.28) 0.01
Prescribed caloric intake per kilogram on day 3 25 (21.25–30) 25 (21.25–28.57) 25 (21.25–29.36) 0.3
Administered caloric intake per kilogram on day 3 24.17 (20–29.45) 22.5 (17.65–26.87) 23.14 (18.69–27.99) 0.003
Prescribed caloric intake per kilogram on day 7 25.84 (22.22–29.94) 25.35 (21.43–30) 25.66 (21.43–30) 0.6
Administered caloric intake per kilogram on day 7 24.72 (20–29.46) 24.06 (19.63–28.57) 24.31 (19.76–28.61) 0.2
Parenthetical values indicate range or percentage. EN, enteral nutrition; ICU, intensive care unit; MCT/LCT, medium-chain triglyceride/long-chain 
triglyceride; TPN, total parenteral nutrition.Available online http://ccforum.com/content/11/1/R10
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Table 4
Demographic data in patients with and without liver dysfunction
With liver dysfunction Without liver dysfunction Total p
Number of patients 166 (23%) 559 (77%) 725
Women 54 (33%) 183 (33%) 237 (33%) 0.9
Age in years 63 (47–72) 63 (44–73) 63 (47–72) 0.8
APACHE II score 18 (14–23) 18 (12–22) 18 (12–22) 0.2
MODS 6 (4–8) 5 (3–7) 5 (3–7) 0.001
Primary diagnosis 0.4
Gastrointestinal surgery 52 126 178
Respiratory failure 26 107 133
Stroke 27 98 125
Cardiovascular 14 72 86
Trauma 16 67 83
Infections in non-immunosuppressed patients 12 28 40
Infections in immunosuppressed patients 3 8 11
Metabolic diseases 1 9 10
Urology 3 7 10
Hematology 1 8 9
Poisoning 2 6 8
Obstetrics/Gynecology 3 4 7
AIDS 1 1 2
Other 5 18 23
Type of patients 0.03
Medical 68 294 362
Surgical 69 195 264
Trauma 29 70 99
Sepsis on admission 68 (41%) 140 25%) 208 (29%) 0.001
Septic shock on admission 33 (20%) 72 (13%) 105 (15%) 0.02
Patients on mechanical ventilation 152 (92%) 469 (84%) 621 (86%) 0.01
Days of mechanical ventilation 13 (6–24) 7 (3–14) 8 (3–16) 0.001
Intensive care unit length of stay in days 16 (8–28) 9 (5–17) 10 (6–20) 0.001
Hospital length of stay in days 28 (17–29) 23 (14–28) 25 (15–29) 0.01
Mortality at 28 days 47 (28.3%) 157 (28.1%) 204 (28%) 0.9
Parenthetical values indicate range or percentage. APACHE II, Acute Physiology and Chronic Health Evaluation II; MODS, Multiple Organ 
Dysfunction Score.Critical Care    Vol 11 No 1    Grau et al.
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appearance of any type of LD and can avoid permanent liver
damage in these patients.
Another factor that could contribute to the low incidence of LD
found in our group is related to the composition of the TPN.
There are studies that emphasize the effect of overfeeding on
the hepatic metabolism [45-47] or suggest that a lipid mixture
containing MCTs (MCT/LCT) could decrease the risk of stea-
tosis or liver cholestasis [48]. Our results do not confirm this
protective effect of the MCT/LCT lipid admixture. The energy
requirements of our patients were calculated at 25 kcal/kg per
day. We have noted a significant difference in the adminis-
tered calories in the TPN group compared with the EN group
on the first and third days of follow-up, as well as a larger
energy intake administered the first day of nutrition in the
group of patients who developed LD. The carbohydrate/fat
ratio (60:40) that we used in this study seems to be safe and
can prevent the abnormalities in liver tests [49].
Conclusion
Our results show that the patients who developed LD have a
characteristic profile in the multivariate analysis. They had a
higher MODS on admission, they were septic, and they were
treated with TPN. The assessment of multiple organ dysfunc-
tion includes among its parameters an LD based on high levels
of bilirubin, so this association should be expected. The liver is
the key organ in the starting and development of multiple
organ dysfunction in the septic patient and plays an essential
Table 5
Nutritional parameters in patients with and without liver dysfunction
With liver dysfunction Without liver dysfunction Total p
166 559 725
Weight in kilograms 75 (65–80) 70 (65–80) 72 (65–80) 0.3
Nutritional status 0.01
Moderate malnutrition 41 (25%) 84 (15%) 125 (17%)
Severe malnutrition 14 (8%) 33 (6%) 47 (7%)
Energy requirements per kilogram 25.54 (24.49–30) 25 (23.33–29.41) 25 (23.64–29.74) 0.04
Type of nutrition 0.001
Enteral 75 (18%) 347 (82%) 422
Parenteral 91 (30%) 212 (70%) 303
Patients receiving MCT/LCT on TPN 75 158 233 0.2
Days on artificial nutrition 13 (8–25) 8 (4–16) 9 (5–8) 0.001
Days on EN 7 (1–17) 6 (0–12) 6 (1–13) 0.2
Days on TPN 5 (0–12) 0 (0–5) 1 (0–7) 0.001
Starting time after ICU admission in days 1 (0.5–2) 1(0–2) 1 (0.2–2) 0.03
Prescribed caloric intake per kilogram on day 1 25 (20.92–29.34) 23.53 (18.75–27.27) 24 (19.3–27.64) 0.01
Administered caloric intake per kilogram on day 1 22.30 (16.88–26.67) 21.43 (16.25–26.15) 21.43 (16.36–26.28) 0.3
Prescribed caloric intake per kilogram on day 3 25 (21.67–30) 24.69 (21.18–28.57) 25 (21.25–29.36) 0.07
Administered caloric intake per kilogram on day 3 23.67 (18.79–28.92) 23.07 (18.70–27.54) 23.14 (18.69–27.99) 0.4
Prescribed caloric intake per kilogram on day 7 26.67 (23.29–30) 25 (20.93–30) 25.66 (21.43–30) 0.06
Administered caloric intake per kilogram on day 7 25 (19.46–29.79) 24.01 (19.85–28.33) 24.31 (19.76–28.61) 0.3
Parenthetical values indicate range or percentage. EN, enteral nutrition; ICU, intensive care unit; MCT/LCT, medium-chain triglyceride/long-chain 
triglyceride; TPN, total parenteral nutrition.Available online http://ccforum.com/content/11/1/R10
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role by clearing endotoxins, bacteria, and derived vasoactive
substances. Sepsis and inflammation can increase the pro-
duction of cytokines, which are potent inhibitors of bile secre-
tion, and the consequent development of cholestasis that can
be enhanced by TPN. Although the negative effects that both
TPN and sepsis exert on hepatic metabolism have previously
been studied independently, this study shows that there is a
greater effect when both conditions, TPN and sepsis, are
present. Also, early artificial nutrition seems to exert a benefi-
cial effect. Notwithstanding prevention and treatment meas-
ures, the presence of sepsis and multiple organ failure should
compel to clinicians to strictly control the caloric intake of seri-
ously ill patients, start artificial nutrition early, and frequently
monitor their liver function.
Competing interests
B. Braun Medical S.A., Cta de Tarrasa 121, 08191 Barcelona,
Spain has financially supported the data acquisition, but with-
out access to the database or results, and will support the arti-
cle-processing charge. TG is a member (vice-coordinator) of
the Spanish Working Group on Metabolism and Nutrition
(section of the Spanish Society of Critical Care). ABo is the
Table 6
Incidence of liver dysfunction
TPN EN Total p OR (95% CI)
Overall patients 303 422 725
Liver dysfunction 91 (30%) 75 (18%) 166 (23%) 0.001 1.7 (1.3–2.2)
Cholestasis 31 (10%) 25 (6%) 56 (8%) 0.03 1.7 (1.04–2.9)
Hepatic necrosis 28 (9%) 20 (5%) 48 (7%) 0.02 1.95 (1.1–3.4)
Mixed pattern 56 (19%) 43 (10%) 99 (14%) 0.001 1.8 (1.3–2.6)
Acalculous cholecystitis 1 2 3
Type of patients and liver dysfunction 91 75 166
Medical 24 (23%) 44 (17%) 68 (19%) 0.3 1.2 (0.8–1.7)
Surgical 55 (31%) 14 (16%) 69 (26%) 0.03 1.8 (1.02–3.1)
Trauma 12 (52%) 17 (23%) 29 (37%) 0.02 2.1 (1.1–4)
Septic patients 122 86 208
Liver dysfunction 47 (39%) 21 (24%) 68 (33%) 0.03 1.6 (1.02–2.4)
Cholestasis 17 (14%) 6 (7%) 23 (11%) 0.1 1.9 (0.8–4.9)
Hepatic necrosis 10 (8%) 3 (4%) 13 (6%) 0.2 2.4 (0.7–8.2)
Mixed pattern 30 (25%) 14 (16%) 44 (21%) 0.1 1.5 (0.9–2.7)
Non-septic patients 181 336 517
Liver dysfunction 44 (24%) 54 (16%) 98 (19%) 0.02 1.5 (1.06–2.2)
Cholestasis 14 (8%) 19 (6%) 33 (6%) 0.4 1.4 (0.7–2.7)
Hepatic necrosis 18 (10%) 17 (5%) 35 (7%) 0.04 2 (1.03–3.7)
Mixed pattern 26 (14%) 29 (9%) 55 (11%) 0.04 1.7 (1.01–2.7)
CI, confidence interval; EN, enteral nutrition; OR, odds ratio; TPN, total parenteral nutrition.
Figure 1
Time free of liver dysfunction in surgical patients treated with Enteral  Nutrition or Total Parenteral Nutrition Time free of liver dysfunction in surgical patients treated with Enteral 
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￿  Sepsis and the use of TPN are the most important con-
ditions that increase the incidence of liver failure.
￿  Cholestasis and the mixed pattern are the most fre-
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￿  Acalculous cholecystitis is an uncommon finding in our 
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